GLP-1 RA vs Bariatric Surgery and Cancer Risk
Glucagon-like peptide-1 receptor agonists compared with bariatric metabolic surgery and the risk of obesity-related cancer: an observational, retrospective cohort studyWolff Sagy, Yael et al. eClinicalMedicine, Volume 83, 103213 This paper presents an observational, retrospective cohort study comparing the incidence of obesity-related cancer (ORC) in adults with obesity and diabetes treated with first-generation GLP-1 receptor agonists (GLP-1 RAs) versus bariatric metabolic surgery (BMS). […]
Cigna, Novo Nordisk offer lower GLP-1 prices
The sun is setting on compounding pharmacies’ ability to make copies of hot weight loss drugs. Pharmacy benefit managers, drugmakers and telehealth companies are lowering their costs to bring patients back to brand-name treatments. …
LifeMD Launches $299 Introductory Wegovy® Bundle for Self-Pay Patients in Collaboration with Novo Nordisk
What You Should Know: – LifeMD, Inc., a provider of virtual primary care services announced a limited-time $299 introductory bundle for new self-pay patients prescribed Wegovy® (semaglutide). – The comprehensive package includes both the GLP-1 medication and access to LifeMD’s virtual weight management program. The initiative is part of LifeMD’s collaboration with Novo Nordisk, announced […]
Novo pressures GLP-1 compounders as FDA ban takes hold
The Danish drugmaker unveiled a series of initiatives to increase access to Wegovy and clamp down on use of the knock-off versions that have dented its sales forecasts.
New rule blocks generic versions of Ozempic and Wegovy
Starting today, pharmacies can no longer make cheaper alternatives to popular weight loss drugs, driving up costs for millions. Dr. Celine Gounder joins to explain what this means for patients.
Allulose Mimics GLP-1 Hormones to Reduce Cravings and Balance Blood Sugar
Be Aware of Lesser-Known Downsides to GLP-1 Weight Loss
Newly recognized issues, including extreme fatigue with excessive weight reduction, bone loss, and abdominal pain, point to the need for ongoing management of patients on GLP-1s, an obesity expert says. Medscape Medical News
THE GLP-1 BLUEPRINT, by Heidi Skolnik
Non-fiction: Health/Medicine | Nutritionist and exercise physiologist Heidi Skolnik’s THE GLP-1 BLUEPRINT
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?
Blockbuster drugs. Rising profits. Strong sales. And yet, Novo Nordisk, the Danish company behind the GLP-1 drugs Ozempic and Wegovy, made a surprising move last week: It pushed out its CEO. WSJ’s Peter Loftus charts the rise of Ozempic and the fall of CEO Lars Jorgensen. Jessica Mendoza hosts. Further Listening: Trillion Dollar Shot Why […]
Cigna debuts GLP-1 copay cap
Cigna subsidiary Evernorth Health Services will automate prior authorizations for GLP-1 weight-loss drugs under a new program